Eledon Pharmaceuticals, Inc. ELDN R2KPHARMA
Company Overview
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +16.15% |
| 6 Months: | +8.63% |
| 3 Months: | -11.44% |
| 1 Month: | -12.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)33.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELDN Eledon Pharmaceuticals, Inc. R2KPHARMA | 3.02 | -3.92 | $233.11M | 0.00% | -28.54% | -72.68% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.96M | 24.73M | 19.07M | 21.48M | 21.18M |
| Operating Income | -6.42M | -6.26M | -13.30M | -8.98M | -11.91M | -11.07M | -11.48M | -932.00K | -1.62M | -3.76M | -1.39M | -6.67M | -2.96M | -2.79M | -3.19M | -3.50M | -4.88M | -4.09M | -2.92M | -3.38M | -2.59M | -6.15M | -9.01M | -7.97M | -10.51M | -9.86M | -9.28M | -10.60M | -11.11M | -10.35M | -11.20M | -10.87M | -14.50M | -20.51M | - | -17.96M | -24.73M | -19.07M | -21.48M | -21.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.96M | -24.73M | -19.07M | -21.40M | -21.18M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.50M | -11.22M | -17.46M | -10.41M | -39.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.39M | -6.21M | -13.26M | -8.96M | -11.85M | -11.02M | -11.43M | -1.00M | -2.04M | -3.74M | -1.37M | -6.66M | -2.97M | -2.81M | -3.19M | -3.50M | -4.88M | -4.09M | -2.89M | -8.18M | -2.59M | -6.14M | -8.50M | -7.38M | -9.82M | -9.86M | -9.25M | -10.47M | -10.77M | -65.76M | -9.91M | -23.63M | -44.91M | 76.97M | - | -6.50M | -11.22M | -17.46M | -10.45M | -39.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.50 | -0.66 | -0.69 | -0.65 | -0.73 | -0.75 | -2.74 | -0.33 | -0.79 | -0.92 | -0.28 | - | -0.08 | -0.13 | -0.21 | - | -0.33 |
| R&D Expense | 2.83M | - | 10.56M | 5.86M | 8.49M | - | 7.93M | 592.00K | 1.05M | - | 479.00K | 533.00K | 517.00K | 1.10M | 1.33M | 1.65M | 2.99M | 2.30M | 1.51M | 1.65M | 832.00K | 615.00K | 5.65M | 4.24M | 7.66M | 6.63M | 5.74M | 7.45M | 8.11M | 7.20M | 7.93M | 7.41M | 10.11M | 16.52M | - | 13.53M | 20.28M | 14.97M | - | 17.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - |
| Operating Income | -9.65M | -15.75M | -23.46M | -45.26M | -5.13M | -13.12M | -14.06M | -16.05M | -18.46M | -36.87M | -88.43M | -43.00M | - | - |
| Net Income | -9.65M | -15.72M | -23.30M | -45.09M | -5.66M | -13.12M | -14.06M | -16.01M | -22.81M | -34.51M | -87.97M | -116.54M | -36.18M | -45.62M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -2.33 | -6.16 | -4.73 | -0.66 | -0.52 |
| R&D Expense | 7.37M | 12.20M | 14.58M | 32.64M | 3.19M | 2.02M | 6.82M | 8.13M | 6.13M | 23.73M | 27.08M | 30.31M | 51.96M | 66.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 32.29M | 107.74M | 67.97M | 1.20M | 20.89M | 17.03M | 10.93M | 197.19M | 170.55M | 92.79M | 89.07M | 177.41M | 169.01M |
| Total Equity | -30.43M | -39.90M | -55.27M | 103.50M | 2.78M | -2.70M | 19.45M | 14.49M | 9.46M | 190.60M | 164.00M | 84.18M | -48.49M | 62.45M | 81.08M |
| Cash & Equivalents | 2.25M | 11.69M | 31.75M | 105.26M | 24.02M | 1.10M | 17.23M | 12.97M | 8.79M | 114.19M | 84.83M | 56.41M | 4.61M | 20.55M | 22.81M |
| Total Liabilities | - | - | 2.21M | 4.24M | 6.25M | 3.90M | 1.44M | 2.53M | 1.47M | 6.59M | 6.55M | 8.61M | 81.86M | 59.27M | 32.23M |
| Current Liabilities | - | - | 2.21M | 4.24M | 6.16M | 2.82M | - | 2.53M | 1.32M | 2.48M | 4.40M | 6.47M | 3.90M | 11.58M | 18.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -14.94M | -11.89M | -13.86M | -15.21M | -28.91M | -28.42M | -39.53M | -47.27M | -62.34M |
| Investing Cash Flow | - | - | - | - | - | 23.26M | - | - | 11.04M | - | - | -45.29M | -70.31M | 10.79M |
| Financing Cash Flow | - | - | - | - | - | 7.87M | 7.56M | 9.68M | 109.58M | -449.00K | - | 33.02M | 133.52M | 53.81M |
| Capital Expenditure | -8.00K | -23.00K | -25.00K | -565.00K | -9.00K | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 24.2% | 28.5% | -22.5% | -1,620.7% | 209.3% | -67.4% | -97.1% | -169.2% | -12.0% | -21.0% | -104.5% | 240.4% | -57.9% | -56.3% |
| ROCE % | - | -52.4% | -22.7% | -73.2% | 316.0% | - | -97.0% | -167.0% | -9.5% | -22.2% | -102.4% | -50.5% | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 7.74% | 6.29M | $20.14M |
| 2 | Blackrock Inc. | 6.31% | 5.12M | $16.40M |
| 3 | Defilade Capital Management, L.P. | 4.34% | 3.53M | $11.28M |
| 4 | Vanguard Capital Management LLC | 4.21% | 3.42M | $10.94M |
| 5 | Goldman Sachs Group Inc | 3.09% | 2.51M | $8.03M |
| 6 | Ensign Peak Advisors, Inc | 2.59% | 2.10M | $6.72M |
| 7 | Geode Capital Management, LLC | 2.41% | 1.96M | $6.26M |
| 8 | Catalio Capital Management, LP | 2.09% | 1.70M | $5.42M |
| 9 | State Street Corporation | 2.00% | 1.62M | $5.19M |
| 10 | Zimmer Partners, Lp | 1.96% | 1.60M | $5.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELDN
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOa1E1MkU3c1ZrQ0lFR1ZaNUY3RlVxWUxzRmpubGk2cDdTUDhUd3R3U0M1eVNzRVJJN0daa2kyUFhIX1VUSktRXzgyLXB4RDd2NXdiUjB4c2w5aTVTekJFQ3h1YllsVHNHX0hHOG9UNzBSVmRBSm5fRjg4a2ZuYjlnZ1JhbWhYVUhacm1DM3…
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOMEFFZXN3Q1FUVlA3M0dVbWdGRkRueUgzMHpXaWZDWTVZbzc4VzhOaV9CeTFWcUtlU3Y4SjU5R1lPS3h4LWM5UmtLLVBuY3R4WEpZT1FsMFotUnlLem15cms3aURoWmtGYzdDRGRuZGgtMDZvVEhYN2N0OTZxaThhUW9XVnZoWXhXYm5YRm…
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9uQWpYTUhKNjVndHRFN3RIVW1EMzdoWXVIZEZHdkExcFo3NXpoaXBpcVh5cUMzTFZPSmNJSkd6bGJ6WEN6VWFKZVFWY1NsYzRJa0g1SUZFNFhfNnN5aE1TeVNYSkxIV1ZXdGVDdUJ1UG9CSml5THlQdHpR?oc=5" target="_blank">ELD…
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOQnBPazNOYlJEQ25JSHN6dkZJU3o3bkNWeG5IQlVXMzBKSDdWTEExOGlQVWtWY3dBMGdBa2R6aTYzTGpQRkI5RDEyaFJnQ3VfMHJ4Q0N5bVRUeGpEdWh2VElMT0lVcGNmSkRwWmRFM2EwMnhzMUFFN3Vrbk55dVBaaWEzcVMwQjZkZ3VEMm…
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNek9FNzl5cHo0STFRaEQwQ3FEX2pPOUxmU1BkSExDamF2UXgyenhEeXA1VEdxV1VidWQ4STAtdkF2aGlTUVNnc0xBUi15U2NnTFNKM0RvMXNLbmpPcXBaS0RKZW1rTEhZM051VDA5TTJUZ1BSalVWWGFfalFpQVlHTGgwR0ZPeF8zdkt3ZW…
ELDN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9BRTE1TXFrRkJscGRXRlhvempvODB2LWRnYXVTblc5VWg1UkFrZk1hXzZMMmlwNzJfdmVkdGRCUkY5TjZlQWc?oc=5" target="_blank">ELDN</a> <font color="#6f6f6f">Finviz</font>…
ELDN — Frequently Asked Questions
What is the current share price of Eledon Pharmaceuticals, Inc. (ELDN)?
As of 2026-09-07 16:24 PDT, Eledon Pharmaceuticals, Inc. (ELDN) trades at $3.02 on NasdaqCM. Its 52-week range is $1.39 to $4.36.
What is the market capitalisation of ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) has a market capitalisation of $233.11M on NasdaqCM.
What is the P/E ratio of ELDN?
ELDN trades at a trailing price-to-earnings (P/E) ratio of -3.92. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.79.
What is the return on equity (ROE) of ELDN?
ELDN has a return on equity (ROE) of -72.68%. Its return on capital employed (ROCE) is -28.54%.
Is ELDN a good stock to buy?
This page provides a data-driven analysis of Eledon Pharmaceuticals, Inc. (ELDN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.